Mutua disponibilità, prezzi e rimborsabilità di farmaci autorizzati con procedura centralizzata europea

The european pharmaceutical market doesn’t seem to be a common integrated european market as far as prices and reimbursements within different countries are concerned. Moreover, to better define such differences, little information is available because of the lack of homogeneous and updated european databases. The aim of this study is to assess mutual availability, prices and reimbursements of innovative drugs authorised by EMEA under European Centralised Procedure between 1995-2000 and marketed in five european countries (Italy, Spain, United Kingdom, France and Denmark). Our results demonstrate that the adoption of different drug-price definition models, within different Member States, is the main cause of the heterogeneity. Currently, in countries adopting a controlled drug-price system, prices are lower than prices set in countries that adopt an uncontrolled drug-price system. In this regard, Italy ranks in a middle position as products marketed in Italy generally have prices lower than in the United Kingdom and Denmark, and higher than in France and Spain. Product availability and level of drug breakthrough in the national markets seem to greatly affect the variations we noted among prices and reimbursements in different countries. Differences we observed emphasize the need of finding a common methodology at european level, in order to define the proven “therapeutic benefit” and the “therapeutic advantage” of innovative drugs, allowing a “right price” and reimbursement to the entitled

The regional distribution of in-hospital fatality among Acute Myocardial Infarction events in Italy

Aim of this paper is to investigate into the differences in the first treatment of Acute Myocardial Infarction (AMI) among Italian regional health care systems, by focusing on the regional distribution of in-hospital deaths. Starting from the theoretical care pathway (from the onset of the illness to hospitalization and recovery or possible death), the in-hospital deaths in each region are decomposed into the contributions of the attack rate, hospitalization and in-hospital fatality. The discrepancies in regional behaviour are investigated, in the aim to assess whether they can be attributed to different performances among Italian regions. The study is based on two data sources: hospital discharges, based on Diagnosis Related Groups (DRG) and provided by the Ministry of Health; death and population data by regions of residence, provided by the National Institute of Statistics

Pricing and reimbursement of pharmaceuticals in Italy

Pharmaceutical pricing, Reimbursement classification, Pharmaceutical policy, Cost containment policy, Innovation, Italy, I18,

Mutua disponibilità, prezzi e rimborsabilità di farmaci autorizzati con procedura centralizzata europea

The european pharmaceutical market doesn’t seem to be a common integrated european market as far as prices and reimbursements within different countries are concerned. Moreover, to better define such differences, little information is available because of the lack of homogeneous and updated european databases. The aim of this study is to assess mutual availability, prices and reimbursements of innovative drugs authorised by EMEA under European Centralised Procedure between 1995-2000 and marketed in five european countries (Italy, Spain, United Kingdom, France and Denmark). Our results demonstrate that the adoption of different drug-price definition models, within different Member States, is the main cause of the heterogeneity. Currently, in countries adopting a controlled drug-price system, prices are lower than prices set in countries that adopt an uncontrolled drug-price system. In this regard, Italy ranks in a middle position as products marketed in Italy generally have prices lower than in the United Kingdom and Denmark, and higher than in France and Spain. Product availability and level of drug breakthrough in the national markets seem to greatly affect the variations we noted among prices and reimbursements in different countries. Differences we observed emphasize the need of finding a common methodology at european level, in order to define the proven “therapeutic benefit” and the “therapeutic advantage” of innovative drugs, allowing a “right price” and reimbursement to the entitled

High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA)

Poor quality of drug prescribing in older persons is often associated with increased drug-related adverse events, hospitalization, and mortality. The present study describes a set of prescribing quality indicators developed by the Geriatrics Working Group of the Italian Medicines Agency (AIFA) and estimates their prevalence in the entire elderly ( 6565 years) population in Italy